Abiopharma

🔍 Smith Robert Lawrence (Executive)

Company: AUBURN NATIONAL BANCORPORATION, INC (AUBN)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 8 shares of common stock, par value $0.01 (Direct)
  Date: 2026-03-10 | Code: A | equity_swap_involved: false | shares_owned_after: 836.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 122 shares of common stock, par value $0.01 at $23.85 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: false | shares_owned_after: 714.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: Represents 8 shares received on March 10, 2026 (the "Settlement Date") as dividend equivalents upon the vesting of 421 restricted stock units.
• F2: Includes drip shares
• F3: 122 shares were withheld by the Issuer from the on the Settlement Date to satisfy tax withholding obligations based on the $23.85 per share closing price on the Nasdaq Global Market on the Settlement Date resulting in the issuance of 299 net shares.
• F4: The reporting person previously reported the grant of 421 restricted stock units as an acquisition of common stock in Table I on July 24, 2025. On the Settlement Date, a total of 307 shares were issued to the Reporting Person.
• REMARKS: This Form 4 is filed late.